RESUMO
Identifying cell type-specific enhancers in the brain is critical to building genetic tools for investigating the mammalian brain. Computational methods for functional enhancer prediction have been proposed and validated in the fruit fly and not yet the mammalian brain. We organized the 'Brain Initiative Cell Census Network (BICCN) Challenge: Predicting Functional Cell Type-Specific Enhancers from Cross-Species Multi-Omics' to assess machine learning and feature-based methods designed to nominate enhancer DNA sequences to target cell types in the mouse cortex. Methods were evaluated based on in vivo validation data from hundreds of cortical cell type-specific enhancers that were previously packaged into individual AAV vectors and retro-orbitally injected into mice. We find that open chromatin was a key predictor of functional enhancers, and sequence models improved prediction of non-functional enhancers that can be deprioritized as opposed to pursued for in vivo testing. Sequence models also identified cell type-specific transcription factor codes that can guide designs of in silico enhancers. This community challenge establishes a benchmark for enhancer prioritization algorithms and reveals computational approaches and molecular information that are crucial for the identification of functional enhancers for mammalian cortical cell types. The results of this challenge bring us closer to understanding the complex gene regulatory landscape of the mammalian brain and help us design more efficient genetic tools and potential gene therapies for human neurological diseases.
RESUMO
Two-dimensional electron gas (2DEG) at the (100) KTaO3(KTO) surface and interfaces has attracted extensive interest because of its abundant physical properties. Here, light illumination-induced semiconductor-metal transition in the 2DEG at the KTO surface was investigated. 2DEG was formed at the surface of KTO by argon ion bombardment. The 2DEG prepared with a shorter bombardment time (300 s) exhibits semiconducting behavior in the range of 20~300 K in the dark. However, it shows a different resistance behavior, namely, a metallic state above ~55 K and a semiconducting state below ~55 K when exposed to visible light (405 nm) with a giant conductivity increase of about eight orders of magnitude at 20 K. The suppression of the semiconducting behavior is found to be more pronounced with increasing light power. After removing the illumination, the resistance cannot recover quickly, exhibiting persistent photoconductivity. More interestingly, the photoresponse of the 2DEG below 50 K was almost independent of the laser wavelength, although the photon energy is lower than the band gap of KTO. The present results provide experimental support for tuning oxide 2DEG by photoexcitation, suggesting promising applications of KTO-based 2DEG in future electronic and optoelectronic devices.
RESUMO
With the increasingly available electronic health records (EHR), disease prediction has recently gained immense research attention, where an accurate classifier needs to be trained to map the input prediction signals (e.g., symptoms, auxiliary examination results, etc.) to the estimated diseases for each patient. However, most of the current disease prediction models focus on the prediction of a single disease; in the medical field, a patient often suffers from multiple diseases (especially multiple chronic diseases) at the same time. Therefore, multi-disease prediction is of greater significance for patients' early intervention and treatment, but there is no doubt that multi-disease prediction has higher requirements for data extraction ability and greater complexity of classification. In this paper, we propose a novel disease prediction model DLKN-MLC. The model extracts the information in EHR through deep learning combined with a disease knowledge network, quantifies the correlation between diseases through NodeRank, and completes multi-disease prediction. in addition, we distinguished the importance of common disease symptoms, occasional disease symptoms and auxiliary examination results in the process of disease diagnosis. In empirical and comparative experiments on real EHR datasets, the Hamming loss, one-error rate, ranking loss, average precision, and micro-F1 values of the DLKN-MLC model were 0.2624, 0.2136, 0.2190, 88.21%, and 87.86%, respectively, which were better compared with those from previous methods. Extensive experiments on a real-world EHR dataset have demonstrated the state-of-the-art performance of our proposed model.
Assuntos
Registros Eletrônicos de Saúde , HumanosRESUMO
OBJECTIVE: The purpose of this study was to evaluate the impact of COVID-19 outbreaks on emergency patients in a resuscitation room in Nanning, China. METHODS: A single-center cross-sectional retrospective study was conducted in the emergency department of a tertiary public hospital from January 1, 2019, to December 31, 2020, in Nanning, Guangxi, China. We collected the data of patients in the resuscitation room to investigate the number of patients accessing emergency services during the study period. Data in 2020 were compared to the data during the same period in 2019. RESULTS: The number of emergency patients in the resuscitation room during the COVID-19 pandemic has decreased in intrinsic diseases, extrinsic diseases, and pediatric cases, especially in the early stages of the pandemic. Additionally, the length of stay of emergency patients in the resuscitation room was reduced. CONCLUSIONS: The number of emergency patients in the resuscitation room during the pandemic of COVID-19 in 2020 was reduced compared to that in the same period in 2019 in Nanning, China. This situation shows a serious social problem, which should arouse the attention of the medical profession and the government.
Assuntos
COVID-19/epidemiologia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Ressuscitação/estatística & dados numéricos , Adulto , Idoso , China , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , SARS-CoV-2RESUMO
ABSTRACT: Our study aims to summarize the clinical characteristics of patients with severe or critically ill coronavirus disease 2019 (COVID-19).Five databases were electronically searched to collect studies describing clinical characteristics of severe or critically ill COVID-19 patients and published between January 1, 2020 and April 12, 2020. Three reviewers independently collected the literature, extracted the required data, and assessed the risk of publication bias of the included studies before including the studies in the meta-analysis.A total of 40 studies involving 2459 patients with severe or critically ill COVID-19 patients were included. Meta-analysis showed that a greater proportion of severe or critically COVID-19 patients were male (62.3%), and the 2 main clinical symptoms were fever (87.4%) and cough (66.3%). Other common clinical symptoms included dyspnea (45.3%), chest tightness (37.4%), fatigue (36.6%), and expectoration (31.9%). Minor symptoms included myalgia (19.5%), dizziness (11.5%), headache (11.4%), diarrhea (11.2%), pharyngalgia (11.0%), nausea, and vomiting (5.9%). Most patients showed elevated levels of C-reactive protein (83.5%) and D-dimer (73.3%), lymphopenia (70.3%), and normal leukocyte counts (56.9%). Other findings included abnormal levels of liver function (39.8%), elevated procalcitonin (36.6%), leukocytosis (21.7%), thrombocytopenia (19.0%), and leucopenia (18.2%). Most patients showed acute respiratory distress syndrome (60.8%). Other complications included acute cardiac injury (37.1%), shock (32.0%), and acute kidney injury (22.0%).The most common symptoms of severe or critically ill COVID-19 patients were fever and cough. Most patients showed lymphopenia, elevated levels of C-reactive protein and D-dimer. A large percentage of patients progress to ARDS, acute cardiac injury, acute kidney injury and shock were also common.
Assuntos
COVID-19 , Tosse , Estado Terminal/terapia , Febre , SARS-CoV-2 , Avaliação de Sintomas/estatística & dados numéricos , COVID-19/sangue , COVID-19/fisiopatologia , Tosse/diagnóstico , Tosse/etiologia , Febre/diagnóstico , Febre/etiologia , Humanos , SARS-CoV-2/isolamento & purificação , SARS-CoV-2/patogenicidade , Índice de Gravidade de DoençaRESUMO
To systematically analyze the blood coagulation features of coronavirus disease 2019 (COVID-19) patients to provide a reference for clinical practice. An electronic search in PubMed, EMbase, Web of Science, Scopus, CNKI, WanFang Data, and VIP databases to identify studies describing the blood coagulation features of COVID-19 patients from 1 January 2020 to 21 April 2020. Three reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies, then, the meta-analysis was performed by using Stata 12.0 software. Thirty-four studies involving 6492 COVID-19 patients were included. Meta-analysis showed that patients with severe disease showed significantly lower platelet count (weighted mean differences [WMD]: -16.29 × 109 /L; 95% confidence interval [CI]: -25.34 to -7.23) and shorter activated partial thromboplastin time (WMD: -0.81 seconds; 95% CI: -1.94 to 0.33) but higher D-dimer levels (WMD: 0.44 µg/mL; 95% CI: 0.29-0.58), higher fibrinogen levels (WMD: 0.51 g/L; 95% CI: 0.33-0.69) and longer prothrombin time (PT; WMD: 0.65 seconds; 95% CI: 0.44-0.86). Patients who died showed significantly higher D-dimer levels (WMD: 6.58 µg/mL; 95% CI: 3.59-9.57), longer PT (WMD: 1.27 seconds; 95% CI: 0.49-2.06) and lower platelet count (WMD: -39.73 × 109 /L; 95% CI: -61.99 to -17.45) than patients who survived. Coagulation dysfunction is common in severe COVID-19 patients and it is associated with severity of COVID-19.
Assuntos
Transtornos da Coagulação Sanguínea/virologia , COVID-19/complicações , COVID-19/mortalidade , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Humanos , Contagem de Leucócitos , Contagem de Plaquetas , Tempo de Protrombina , Fatores de RiscoRESUMO
Our study aimed to assess the existing evidence on whether severe coronavirus disease 2019 (COVID-19) is associated with elevated inflammatory markers.The PubMed, Embase, Web of Science, Scopus, Chinese National Knowledge Infrastructure, WanFang, and China Science and Technology Journal databases were searched to identify studies published between January 1 and April 21, 2020 that assayed inflammatory markers in COVID-19 patients. Three reviewers independently examined the literature, extracted relevant data, and assessed the risk of publication bias before including the meta-analysis studies.Fifty-six studies involving 8719 COVID-19 patients were identified. Meta-analysis showed that patients with severe disease showed elevated levels of white blood cell count (WMD: 1.15, 95% CI: 0.78-1.52), C-reactive protein (WMD: 38.85, 95% CI: 31.19-46.52), procalcitonin (WMD: 0.08, 95% CI: 0.06-0.11), erythrocyte sedimentation rate (WMD: 10.15, 95% CI: 5.03-15.46), interleukin-6 (WMD: 23.87, 95% CI: 15.95-31.78), and interleukin-10 (WMD: 2.12, 95% CI: 1.97-2.28). Similarly, COVID-19 patients who died during follow-up showed significantly higher levels of white blood cell count (WMD: 4.11, 95% CI: 3.25-4.97), C-reactive protein (WMD: 74.18, 95% CI: 56.63-91.73), procalcitonin (WMD: 0.26, 95% CI: 0.11-0.42), erythrocyte sedimentation rate (WMD: 10.94, 95% CI: 4.79-17.09), and interleukin-6 (WMD: 59.88, 95% CI: 19.46-100.30) than survivors.Severe COVID-19 is associated with higher levels of inflammatory markers than a mild disease, so tracking these markers may allow early identification or even prediction of disease progression.
Assuntos
Betacoronavirus , Biomarcadores/sangue , Infecções por Coronavirus/sangue , Mediadores da Inflamação/sangue , Pneumonia Viral/sangue , Índice de Gravidade de Doença , Adulto , Idoso , Sedimentação Sanguínea , Proteína C-Reativa/análise , COVID-19 , Infecções por Coronavirus/mortalidade , Progressão da Doença , Feminino , Humanos , Inflamação , Interleucina-10/sangue , Interleucina-6/sangue , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/mortalidade , Pró-Calcitonina/sangue , SARS-CoV-2RESUMO
Our study aimed to systematically analyse the risk factors of coronavirus disease 2019 (COVID-19) patients with severe disease. An electronic search in eight databases to identify studies describing severe or critically ill COVID-19 patients from 1 January 2020 to 3 April 2020. In the end, we meta-analysed 40 studies involving 5872 COVID-19 patients. The average age was higher in severe COVID-19 patients (weighted mean difference; WMD = 10.69, 95%CI 7.83-13.54). Patients with severe disease showed significantly lower platelet count (WMD = -18.63, 95%CI -30.86 to -6.40) and lymphocyte count (WMD = -0.35, 95%CI -0.41 to -0.30) but higher C-reactive protein (CRP; WMD = 42.7, 95%CI 31.12-54.28), lactate dehydrogenase (LDH; WMD = 137.4, 95%CI 105.5-169.3), white blood cell countï¼WBC), procalcitoninï¼PCTï¼, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinineï¼Crï¼. Similarly, patients who died showed significantly higher WBC, D-dimer, ALT, AST and Cr but similar platelet count and LDH as patients who survived. These results indicate that older age, low platelet count, lymphopenia, elevated levels of LDH, ALT, AST, PCT, Cr and D-dimer are associated with severity of COVID-19 and thus could be used as early identification or even prediction of disease progression.
Assuntos
Infecções por Coronavirus/epidemiologia , Linfopenia/epidemiologia , Pneumonia Viral/epidemiologia , Trombocitopenia/epidemiologia , Fatores Etários , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Betacoronavirus , Proteína C-Reativa/metabolismo , COVID-19 , Infecções por Coronavirus/sangue , Infecções por Coronavirus/mortalidade , Infecções por Coronavirus/fisiopatologia , Creatinina/sangue , Estado Terminal , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Humanos , L-Lactato Desidrogenase/sangue , Contagem de Leucócitos , Contagem de Linfócitos , Linfopenia/sangue , Pandemias , Contagem de Plaquetas , Pneumonia Viral/sangue , Pneumonia Viral/mortalidade , Pneumonia Viral/fisiopatologia , Pró-Calcitonina/sangue , Fatores de Risco , SARS-CoV-2 , Índice de Gravidade de Doença , Trombocitopenia/sangueRESUMO
OBJECTIVE: Our study aims to present a summary of the clinicopathological characteristics of patients affected by the coronavirus disease 2019 (COVID-19) that can be used as a reference for further research and clinical decisions. DESIGN: Studies were included in the meta-analysis if they had cohort, case-control or case series designs and provided sufficient details on clinical symptoms, laboratory outcomes and asymptomatic patients. SETTING: PubMed, Embase, Chinese Biomedical Literature Database, Wanfang, China Science and Technology Journal Database and China National Knowledge Infrastructure databases were electronically searched to identify related studies published between 1 January 2020 and 16 March 2020. Three reviewers independently examined the literature, extracted relevant data and assessed the risk of publication bias before including the studies in the meta-analysis. PARTICIPANTS: The confirmed cases of COVID-19. RESULTS: A total of 55 unique retrospective studies involving 8697 patients with COVID-19 were identified. Meta-analysis showed that a higher proportion of infected patients were male (53.3%), and the two major symptoms observed were fever (78.4%) and cough (58.3%). Other common symptoms included fatigue (34%), myalgia (21.9%), expectoration (23.7%), anorexia (22.9%), chest tightness (22.9%) and dyspnoea (20.6%). Minor symptoms included nausea and vomiting (6.6%), diarrhoea (8.2%), headache (11.3%), pharyngalgia (11.6%), shivering (15.2%) and rhinorrhea (7.3%). About 5.4% of the patients were asymptomatic. Most patients showed normal leucocyte counts (64.7%) and elevated C reactive protein levels (65.9%). Lymphopaenia was observed in about 47.6% of the infected patients, along with abnormal levels of myocardial enzymes (49.4%) and liver function (26.4%). Other findings included leucopenia (23.5%), elevated D-dimer (20.4%), elevated erythrocyte sedimentation rate (20.4%), leucocytosis (9.9%), elevated procalcitonin (16.7%) and abnormal renal function (10.9%). CONCLUSIONS: The most commonly experienced symptoms of patients with COVID-19 were fever and cough. Myalgia, anorexia, chest tightness and dyspnoea were found in some patients. A relatively small percentage of patients were asymptomatic and could act as carriers of the disease. Most patients showed normal leucocyte counts, elevated levels of C reactive protein and lymphopaenia, confirming the viral origin of the disease.
Assuntos
Infecções por Coronavirus/fisiopatologia , Pneumonia Viral/fisiopatologia , COVID-19 , China/epidemiologia , Infecções por Coronavirus/epidemiologia , Humanos , Pandemias , Pneumonia Viral/epidemiologia , Estudos RetrospectivosRESUMO
Psoriasis is a chronic inflammatory disease characterized by immunological imbalance and vasodilation. Many triggering factors for psoriasis initiate inflammation via the activation of NF-κB. Narrow-band ultraviolet B (NB-UVB) irradiation can be used as a general treatment for psoriasis, although the molecular mechanism has not yet been determined. The aim of this study was to elucidate the potential molecular mechanism of NB-UVB irradiation therapy on psoriasis. We collected serum samples from patients with psoriasis and healthy control, and detected the expression of inflammatory factors by ELISA. In addition, we established mouse model of psoriasis. After different doses of NB-UVB irradiation, the proportion of CD4+ , CD8+ , and CD11c+ cells in mouse spleen was detected by flow cytometry. Meanwhile, the expression of inflammatory factors in the damaged skin of mice was detected by RT-PCR and Western blot analysis, and mouse serum levels of inflammatory factors were detected by ELISA. Our results showed that NB-UVB irradiation regulated the expression of inflammatory factors in psoriasis patients. In mice, high-dose NB-UVB irradiation effectively eliminated IMQ-induced psoriasis-like dermatitis and inhibited the expression of pro-inflammatory factors. In conclusion, our results indicate that NB-UVB irradiation could regulate the expression of inflammatory factors and attenuate psoriasis plaques.
Assuntos
Psoríase , Terapia Ultravioleta , Animais , Humanos , CamundongosRESUMO
OBJECTIVE: We systematically reviewed the computed tomography (CT) imaging features of coronavirus disease 2019 (COVID-19) to provide reference for clinical practice. METHODS: Our article comprehensively searched PubMed, FMRS, EMbase, CNKI, WanFang databases, and VIP databases to collect literatures about the CT imaging features of COVID-19 from 1 January to 16 March 2020. Three reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies, and then, this meta-analysis was performed by using Stata12.0 software. RESULTS: A total of 34 retrospective studies involving a total of 4121 patients with COVID-19 were included. The results of the meta-analysis showed that most patients presented bilateral lung involvement (73.8%, 95% confidence interval [CI]: 65.9%-81.1%) or multilobar involvement (67.3%, 95% CI: 54.8%-78.7%) and just little patients showed normal CT findings (8.4%). We found that the most common changes in lesion density were ground-glass opacities (68.1%, 95% CI: 56.9%-78.2%). Other changes in density included air bronchogram sign (44.7%), crazy-paving pattern (35.6%), and consolidation (32.0%). Patchy (40.3%), spider web sign (39.5%), cord-like (36.8%), and nodular (20.5%) were common lesion shapes in patients with COVID-19. Pleural thickening (27.1%) was found in some patients. Lymphadenopathy (5.4%) and pleural effusion (5.3%) were rare. CONCLUSION: The lung lesions of patients with COVID-19 were mostly bilateral lungs or multilobar involved. The most common chest CT findings were patchy and ground-glass opacities. Some patients had air bronchogram, spider web sign, and cord-like. Lymphadenopathy and pleural effusion were rare.
Assuntos
Betacoronavirus/patogenicidade , Técnicas de Laboratório Clínico/métodos , Infecções por Coronavirus/diagnóstico por imagem , Linfadenopatia/diagnóstico por imagem , Pandemias , Derrame Pleural/diagnóstico por imagem , Pneumonia Viral/diagnóstico por imagem , Betacoronavirus/genética , Biomarcadores/análise , COVID-19 , Teste para COVID-19 , China/epidemiologia , Infecções por Coronavirus/complicações , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Humanos , Pulmão/diagnóstico por imagem , Pulmão/patologia , Linfadenopatia/complicações , Linfadenopatia/epidemiologia , Derrame Pleural/complicações , Derrame Pleural/epidemiologia , Pneumonia Viral/complicações , Pneumonia Viral/epidemiologia , Estudos Retrospectivos , SARS-CoV-2 , Índice de Gravidade de Doença , Tomografia Computadorizada por Raios XRESUMO
PURPOSE: This study examined whether the neuroprotective drug, 3-n-butylphthalide (NBP), which is used to treat ischemic stroke, prevents mitochondrial dysfunction. MATERIALS AND METHODS: PC12 neuronal cells were pretreated for 24 hours with NBP (10 µmol/L), then exposed to oxygen and glucose deprivation (OGD) for 8 hours as an in vitro model of ischemic stroke. Indices of anti-oxidative response, mitochondrial function and mitochondrial dynamics were evaluated. RESULTS: OGD suppressed cell viability, induced apoptosis and increased caspase-3 activity. NBP significantly reversed these effects. NBP prevented oxidative damage by increasing the activity of superoxide dismutase and lowering levels of malondialdehyde (MDA) and reactive oxygen species (ROS). At the same time, it increased expression of Nrf2, HO-1 and AMPK. NBP attenuated mitochondrial dysfunction by enhancing mitochondrial membrane potential and increasing the activity of mitochondrial respiratory chain complexes I-IV and ATPase. NBP altered the balance of proteins regulating mitochondrial fusion and division. CONCLUSION: NBP exerts neuroprotective actions by enhancing anti-oxidation and attenuating mitochondrial dysfunction. Our findings provide insight into how NBP may exert neuroprotective effects in ischemic stroke and raise the possibility that it may function similarly against other neurodegenerative diseases involving mitochondrial dysfunction.
Assuntos
Antioxidantes/farmacologia , Benzofuranos/farmacologia , Isquemia Encefálica/tratamento farmacológico , Mitocôndrias/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Acidente Vascular Cerebral/tratamento farmacológico , Animais , Apoptose/efeitos dos fármacos , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patologia , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Mitocôndrias/metabolismo , Mitocôndrias/patologia , Dinâmica Mitocondrial/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Células PC12 , Ratos , Transdução de Sinais/efeitos dos fármacos , Acidente Vascular Cerebral/metabolismo , Acidente Vascular Cerebral/patologiaRESUMO
Purpose: The aim of this study was to generate a novel miRNA expression signature to effectively assess nodal metastasis, distant metastasis and predict prognosis for patients with kidney renal clear cell carcinoma (KIRC) and explore its potential mechanism of affecting the prognosis. Method: Using expression profiles downloaded from the Cancer Genome Atlas database, we identified multiple miRNAs with differential expression between KIRC and paired normal tissues. The diagnostic values of the differentially expressed miRNAs for nodal metastasis and distant metastasis were evaluated by Receiver Operating Characteristic (ROC) curve analysis. Then, we evaluated the impact of miRNAs on overall survival (OS) by univariate and multivariate COX regression analyzes. This analysis was ultimately used to construct a miRNA signature that effectively assessed nodal metastasis, distant metastasis and predicted prognosis. The functional enrichment analysis of the miRNAs included in the signatures was used to explore its potential molecular mechanism in KIRC. Results: Based on our cutoff criteria (P < 0.05 and |log2FC| > 1.0), we identified 104 differentially expressed microRNAs (miRNAs), including 43 that were up-regulated in KIRC tissues and 61 that were down-regulated. We found 12 miRNAs were potentially diagnostic biomarkers of nodal metastasis and distant metastasis by ROC curve analysis. Two miRNAs (miRNA-21 and miRNA-223) were significant miRNAs independently associated with OS based on Cox univariate and multivariate analysis. We generated a signature index based on expression of these two miRNAs, and the two-miRNA signature is promising as a biomarker for diagnosing nodal metastasis, distant metastasis and predicting 5-year survival rate of KIRC with areas under the curve (AUC)=0.738, 0.659 and 0.731, respectively. Patients were stratified into high-risk and low-risk groups, according to median of the signature prognosis indexes. Patients in the high-risk group had significantly shorter survival times than those in the low-risk group (P = 0.000). The functional enrichment analysis suggested that the target genes of two miRNAs may be involved in various pathways related to cancer, p53 signaling pathway, apoptosis, and MAPK signaling pathway. Conclusion: The two-miRNA signature could assess nodal metastasis, distant metastasis and predict survival of KIRC. As a promising prediction tool, the mechanism of the two miRNAs in KIRC deserves further study.
RESUMO
BACKGROUND: There have been several studys about transbronchial needle aspiration (TBNA) combined with rapid on-site evaluation (ROSE) so far at home and abroad, yet few studys were especially for patients with lung cancer. The aim of our study is to investigate the effect of TBNA combined with ROSE in the diagnosis of lung cancer. METHODS: The data of the patients from December 2012 to December 2013, who were performed with TBNA and ultimately diagnosed with lung cancer in the People's Hospital of Binzhou City, were retrospectively analyzed. The patients were divided into two groups, ROSE group (rapid on-site evaluation group) and no-ROSE group (the group without rapid on-site evaluation). Among these patients, 37 patients were in the ROSE group and 32 patients were in the no-ROSE group. The result of ROSE and HE stain, the diagnostic yields and needle passes of each lymph node, the complication and cytology diagnostic cost of TBNA with ROSE and without ROSE were compared. RESULTS: The coherence of ROSE and HE stain was 94.1% (32/34). The diagnostic yields of TBNA were 91.9% (34/37) and 78.1% (25/32) in ROSE group and no-ROSE group respectively, no significant differences were found. But the median number of needle passes of each lymph node and the percentage of the complication in ROSE group and no-ROSE group was significantly lower (t=29.5, P<0.05 and χ(2)=4.4, P<0.05, respectively). The cytopathological diagnostic cost of ROSE group was significantly lower compared with no-Rose group (t=10.9, P<0.05). CONCLUSIONS: TBNA combined with ROSE has good concordance with HE stain in the diagnosis of lung cancer, and could reduce the needle passes, cytopathological diagnostic cost and complication, worthy of popularized.